2 overlooked stocks that crushed earnings but traded lower
As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results. Regardless of sector or industry, every earnings ...
Bristol Myers Squibb: Bright Future Ahead
Bristol Myers Squibb is facing short-term pressure on financial results due to generic growth impacting its flagship drug Revlimid. BMY is actively investing in new drugs and companies to strengthe...
Bristol Myers (BMY) Receives FDA Approval for NSCLC Drug
Bristol Myers' (BMY) repotrectinib, a tyrosine kinase inhibitor (???TKI???) targeting ROS1 oncogenic fusions, gets FDA?
US FDA approves Bristol-Myers' lung cancer drug
The U.S. Food and Drug Administration (FDA) on Wednesday approved Bristol-Myers' drug to treat patients with a type of lung cancer.
Bristol Myers Squibb Proved in Q3 Why Its Diverse Portfolio Makes It a Solid Investment
Sales of Revlimid fell 41% last quarter, and yet Bristol Myers' top line was down just 2%. The company has been bolstering its portfolio of new products over the years, and that appears to be payin...
High-yield, low-beta value plays for buy-and-hold investors
With risk omnipresent in the market and more reason than 1 to fear a recession, value, yield, and beta are more critical for successful investing than ever. If nothing else, volatility should be ex...
Bristol-Myers Squibb Company (BMY) Management Presents at 2023 UBS BioPharma Conference (Transcript)
Bristol-Myers Squibb Company (NYSE:BMY ) 2023 UBS BioPharma Conference Transcript November 8, 2023 8:00 AM ET Executives Lynelle Hoch - Head, Cell Therapy Analysts Trung Huynh - UBS Trung Huynh Oka...
Merck and Bristol Myers Squibb Will Face Off in This 1 Market -- but Who Will Win?
Merck and Bristol Myers Squibb are developing antibody-drug conjugates. Both are acquiring biotechs and assets to beef up their pipelines.
Fortunes Can Be Made With Bristol-Myers Squibb
Since early July, Bristol-Myers Squibb Co.'s (BMY, Financial) share price has been under downward pressure due, in part, to growing concerns among financial market participants about the ability of...
3 No-Brainer Stocks to Buy With $500 Right Now
The major stock indexes have bounced back and forth between bull and bear markets since the start of the decade. Most online brokerages have done away with investment-related barriers to entry (e.g.
Biotech/Drug Stocks Q3 Earnings Due Nov 7: GILD, PRGO, VTRS & More
Let us take a look at what's in store for biotech/drug stocks GILD, PRGO, VTRS, SAGE and IOVA, which are scheduled to report on Nov 7.
Bristol Myers Squibb Revenue Falls on Generic Competition for Key Drug
Shares of Bristol Myers Squibb (BMY) fell Thursday after the company reported that sales of the drug maker's popular Revlimid blood cancer treatment plunged due to competition from generics.
Bristol Myers Squibb (BMY) Surpasses Q3 Earnings and Revenue Estimates
Bristol Myers Squibb (BMY) came out with quarterly earnings of $2 per share, beating the Zacks Consensus Estimate of $1.76 per share. This compares to earnings of $1.99 per share a year ago.
Bristol-Myers Squibb earnings top estimates
Bristol-Myers Squibb Co. BMY, +0.87% on Thursday posted net income of $1.928 billion, or 93 cents a share, for the third quarter, up from $1.606 billion, or 75 cents a share, in the year-earlier pe...
Bristol Myers Squibb earnings top estimates even as top-selling drug fights generic competition
Bristol Myers Squibb's revenue was in line with estimates, but fell slightly from the same period last year due to lower sales of blood cancer drug Revlimid.
Related Companies